Somapacitan was noninferior to somatropin in improving yearly growth rate in ... According to Novo Nordisk, results from the TS substudy will be available later this year. Regulatory submission for ...

which may better suit the needs of children with growth failure. These encouraging results from REAL8 mark a significant step forward in achieving that commitment.” 1 In April 2025, Novo Nordisk ...

Results from the Phase III REAL8 basket study show that Novo Nordisk’s Sogroya (somapacitan) demonstrated significant efficacy and was well-tolerated in children with growth disorders, including those ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk ... s daily growth hormone in children with Noonan syndrome (NS) and in children born small for gestational age (SGA ...

Novo Nordisk has shared positive trial results from the Phase III REAL8 basket study of once-weekly growth hormone Sogroya (somapacitan) in pre-pubertal children born small for gestational age (SGA), ...

Novo Nordisk A/S (NYSE ... in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short ...

Superiority was achieved for once-weekly somapacitan versus daily growth hormone in children with NS 2, as well as compared to lower doses of daily growth hormone in children born SGA 1 ... treatment ...

Novo Nordisk ... s growth disorders in a Phase III trial. The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for gestational age ...

(RTTNews) - Novo Nordisk A/S (NVO ... was non-inferior to once-daily growth hormone treatment at Week 52 across three indications - small for gestational age, Noonan syndrome , and idiopathic ...

Sogroya showed 11.0 cm/year growth in SGA children vs 9.4 cm/year with low ... and expert insights—now 60%. Novo Nordisk A/S NVO on Monday presented data from the phase 3 REAL8 basket study ...